Selective MASP-2 Inhibitors for Complement Pathway Control
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for MASP-2-associated diseases and disorders are inadequate, particularly for conditions not effectively addressed by large molecule biologic inhibitors, highlighting a need for alternative therapeutic agents that can selectively inhibit MASP-2 without interfering with the classical complement activation pathway.
Innovation Solution
Development of synthetic compounds, including those represented by Structures (I), (II), and (III), which are designed to selectively inhibit MASP-2 over thrombin, offering a pharmaceutical composition for treating MASP-2-associated diseases and disorders without affecting the classical complement pathway.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If large molecule biologic inhibitors are used to treat MASP-2-associated diseases, then MASP-2 inhibition is achieved, but the treatment is inadequate for certain conditions and lacks selectivity over other proteases
Solution Approach 1:
The patent transforms the therapeutic agent from large molecule biologics to small molecule compounds, fundamentally changing the molecular size parameter. This enables better tissue penetration and oral bioavailability while maintaining MASP-2 inhibition efficacy, thereby expanding treatment applicability to various disease conditions including those not responsive to biologic inhibitors
2Reliability
If MASP-2 inhibition is achieved, then lectin pathway complement activity is blocked, but there is risk of interfering with classical complement activation pathway
Solution Approach 1:
The small molecule inhibitors are designed with specific molecular features that confer selective binding to MASP-2's active site while lacking affinity for classical pathway components. This localized molecular recognition ensures inhibition is confined to the lectin pathway, preserving classical pathway function and avoiding harmful cross-interference
3Adaptability or versatility
If small molecule compounds are developed to inhibit MASP-2, then selectivity over thrombin and other proteases can be achieved, but compound design and optimization becomes more complex
Solution Approach 1:
The MASP-2 inhibitor molecules are designed as segmented structures with distinct functional domains: a warhead group for active site covalent bonding, a linker region for spacing and flexibility, and aromatic rings for hydrophobic interactions and selectivity. This modular segmentation enables systematic optimization of selectivity while managing molecular complexity
4Ease of operation
If synthetic small molecule inhibitors are used instead of biologic inhibitors, then oral administration and better pharmacokinetics are possible, but the compounds must achieve sufficient potency and selectivity
Solution Approach 1:
The patent replaces the mechanical/biological delivery system of biologic inhibitors (requiring injection) with chemically stable small molecules suitable for oral administration. The small molecules incorporate bioisosteric replacements and metabolic stability features that maintain potency while enabling gastrointestinal absorption and appropriate pharmacokinetic profiles
Data Source
AI summary
The present disclosure provides, inter alia, compounds with MASP-2 inhibitory activity, compositions of such compounds, and methods of making and using such compounds.